Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. News about Disc Medicine frequently centers on its investigational pipeline, which targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Coverage of IRON often highlights regulatory and clinical milestones for bitopertin, DISC-0974, and DISC-3405. The company has reported submitting a New Drug Application for bitopertin in erythropoietic protoporphyria under the FDA’s accelerated approval pathway and receiving a Commissioner’s National Priority Voucher, a program designed to shorten review times for certain drugs. Updates also include progress in the APOLLO confirmatory trial of bitopertin.
Disc Medicine news also features data readouts and conference presentations. For DISC-0974, the company has reported initial Phase 2 results in anemia of myelofibrosis, describing substantial reductions in hepcidin, increases in iron, and positive effects on measures of anemia, as well as participation in major hematology meetings. For DISC-3405, Disc has announced Phase 2 and Phase 1b studies in polycythemia vera and sickle cell disease and has shared trial design information at scientific conferences.
Investors following IRON news will also see announcements related to public offerings of common stock and pre-funded warrants, updates on cash position and financial results, and corporate developments such as board changes, leadership appointments, and participation in investor and healthcare conferences. This combination of clinical, regulatory, financial, and corporate updates provides context for understanding Disc Medicine’s development-stage profile and strategic priorities.
Disc Medicine has secured exclusive rights to MWTX-003, an anti-TMPRSS6 antibody, following an agreement with Mabwell Therapeutics. This drug, which shows promise in treating beta-thalassemia and polycythemia vera, has received FDA acceptance for its Investigational New Drug (IND) application. A phase 1 study is set to commence in the second half of 2023. The agreement includes a $10 million upfront payment, with potential total payments reaching $412.5 million, plus royalties on sales. Disc's focus is on developing treatments for serious hematologic diseases through innovation in iron homeostasis.
Disc Medicine has successfully merged with Gemini Therapeutics, finalized on December 29, 2022, enabling the combined entity to trade under the ticker symbol IRON on Nasdaq. With approximately $175 million in cash and equivalents following a $53.5 million financing round, Disc aims to advance its hematology programs and enhance its clinical pipeline through key trials including bitopertin and DISC-0974. The merger positions Disc for significant growth in addressing hematologic diseases while ensuring operational viability into 2025.